Recent Publications from PubMed

• The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes.
  Greaney AJ, Eguia RT, Starr TN, Khan K, Franko N, Logue JK, Lord SM, Speake C, Chu HY, Sigal A, Bloom JD
  PLoS pathogens. 2022 Jun; 18 6: e1010592
• Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution.
  Starr TN, Greaney AJ, Hannon WW, Loes AN, Hauser K, Dillen JR, Ferri E, Farrell AG, Dadonaite B, McCallum M, Matreyek KA, Corti D, Veesler D, Snell G, Bloom JD
  Science (New York, N.Y.). 2022 Jun; : eabo7896
• Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.
  Tortorici MA, Walls AC, Joshi A, Park YJ, Eguia RT, Miranda MC, Kepl E, Dosey A, Stevens-Ayers T, Boeckh MJ, Telenti A, Lanzavecchia A, King NP, Corti D, Bloom JD, Veesler D
  Cell. 2022 Jun; 185 13: 2279-2291.e17
• An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain.
  Greaney AJ, Starr TN, Bloom JD
  Virus evolution. 2022 ; 8 1: veac021
• Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.
  Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, Helms L, Zhao YT, Hsiang TY, Starr TN, Goreshnik I, Kozodoy L, Carter L, Ravichandran R, Green LB, Matochko WL, Thomson CA, Vögeli B, Krüger A, VanBlargan LA, Chen RE, Ying B, Bailey AL, Kafai NM, Boyken SE, Ljubetič A, Edman N, Ueda G, Chow CM, Johnson M, Addetia A, Navarro MJ, Panpradist N, Gale M, Freedman BS, Bloom JD, Ruohola-Baker H, Whelan SPJ, Stewart L, Diamond MS, Veesler D, Jewett MC, Baker D
  Science translational medicine. 2022 May; 14 646: eabn1252